Maria Abreu, MD
- ADJUNCT ASSOCIATE PROFESSOR | Medicine, General Internal Medicine
Abreu MT. Nod2 in normal and abnormal intestinal immune function. Gastroenterology 2005 October; 129(4): 1302-1304.
Abreu MT. Effectiveness of controlled-release budesonide in preserving bone mineral density in patients with Crohn's disease. Nat Clin Pract Gastroenterol Hepatol 2005 May; 2(5): 210-211.
Sands BE, Abreu MT, Ferry GD, Griffiths AM, Hanauer SB, Isaacs KL, Lewis JD, Sandborn WJ, Steinhart AH. Design issues and outcomes in IBD clinical trials [review]. Inflamm Bowel Dis 2005 November; 1: S22-28.
Rochester J, Abreu MT. Ulcerative colitis therapy: importance of delivery mechanisms [review]. Rev Gastroenterol Disord 2005 Fall; 5(4): 215-222.
Abreu MT, Geller JL, Vasiliauskas EA, Kam LY, Vora P, Martyak LA, Yang H, Hu B, Lin YC, Keenan G, Price J, Landers CJ, Adams JS, Targan SR. Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn's disease. J Clin Gastroenterol 2006 January; 40(1): 55-63.
Abreu MT. Serologies in Crohn's disease: can we change the gray zone to black and white?. Gastroenterology 2006 August; 131(2): 664-667.
Lichtenstein GR, Abreu M, Cohen R, Tremaine W. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease [review]. Gastroenterology 2006 March; 130(3): 940-987.
Lichenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006 March; 130(3): 935-939.